BBLG Bone Biologics Corp.: Debt to Equity
The market trend for the total debt-to-equity ratio of Bone Biologics (BBLG) is 0.00. This price action is supported by the conduct of rigorous trials for new bone materials under FDA supervision. Bone Biologics (BBLG) creates unique NELL-1 protein systems for spinal repair, ensuring ideal tissue regeneration. Currently, the business generates revenue through external funding while focusing on biological developments for dentistry and neurosurgery.
%20Aggregate%20Debt%20to%20Equity&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_BBLG_-_Bone-Biologics_-_Aggregate-Debt-to-Equity "Bone Biologics Corporation - BBLG Total Debt to Capital (period 07/04/2022 - 10/29/2026) | 👁️GURU.Markets👁️")
BBLG (Bone Biologics Inc): analytical breakdowns and indicator data
Investors utilize leverage multiples to verify an issuer's financial stability and assess bankruptcy risks. Analyzing changes in the total debt-to-equity ratio allows for a comparison of total liabilities against the equity of Bone Biologics (BBLG), which, given a lean staff and a reliance on external consultants, confirms cost management efficiency without excessive leverage of operational activities.